Juliana da Silva, M.D., is a physician, epidemiologist, and public health expert at the U.S. Centers for Disease Control and Prevention (CDC), where she leads the Viral Suppression and ARV Outcomes Team within the Division of Global HIV and Tuberculosis. In this role, she provides evidence-based strategic direction to national HIV programs supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), focusing on antiretroviral (ARV) optimization, viral load testing, adherence strategies, and HIV drug resistance.
Board-certified in Infectious Diseases and trained in Tropical Medicine and Public Health, Dr. da Silva brings more than 15 years of experience advancing global health through clinical care, program implementation, and applied research. Her areas of expertise include disease surveillance, antimicrobial resistance, outbreak response, health systems strengthening and the design and execution of cohort studies, case-control studies, and clinical trials.
A skilled global health diplomat, Dr. da Silva collaborates with ministries of health, academic institutions, and nonprofit organizations in resource-limited settings to deliver technical assistance, shape policy, and lead operational research in diverse and complex environments.
Her research centers on optimizing the clinical management of individuals failing standard HIV treatment. She leads an international drug resistance surveillance network (CADRE) and investigates the efficacy of long-acting antiretrovirals through her role as a member of the AIDS Clinical Trials Group (ACTG). Dr. da Silva is an advisor to the World Health Organization’s HIVResNet and a member of the HIV Drug Resistance Surveillance Technical Working Group. She is a trusted advisor to scientific and clinical trial boards, guiding research priorities and the design of HIV therapeutic studies.
